News

Joint position statement on the use of generic Eltrombopag

From October 2025, the UK will have access to generic eltrombopag.  Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licenced treatments for immune thrombocytopenia (ITP).

The ITP Clinical Forum and the ITP Support Association have prepared a joint-statement on the use of generic eltrombopag.

This document is in PDF format. Position statement Generic TPO RA from ITP Forum and the ITPSA